The new Marek's disease vaccine virus 301B/1 is nonpathogenic and shows promising replicative characteristics, making it a strong candidate for commercial vaccine use.
No takes yet. Share an insight, caveat, or question.
301B/1 merits testing in commercial poultry; animal data leave open field efficacy and safety.
Witter et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: